Clinical Trials Logo

Clinical Trial Summary

The gold standard for characterizing chronic kidney disease (CKD) is the glomerular filtration rate (GFR), which is commonly estimated in both native and transplanted kidneys for patient monitoring and therapeutic management and ultimately guides decision-making about whether a patient needs renal replacement therapy. In particular, the National Kidney Foundation has defined CKD stages according to estimated GFR (eGFR) values and in several studies, the eGFR slope or change has been found to be strongly associated with end stage renal disease (ESRD).

However, little is known about the heterogeneity of eGFR evolution in time - i.e. eGFR trajectories - and the related progression to ESRD and death. To date, no studies have investigated eGFR trajectories in diversified cohorts and populations worldwide, although this approach could provide a better understanding of CKD evolution and hence improve risk stratification. In addition, determinants of eGFR trajectories remain poorly described.

An unsupervised approach could allow examining eGFR trajectories over time and could lead to the identification of patient groups according to the probability of the progression of their kidney disease.

Therefore, this study aims:

1. To identify the long-term eGFR trajectories after kidney transplantation using latent class mixed models;

2. To identify the clinical, immunological, histological and functional determinants of the eGFR trajectories using multinomial regressions;

3. To investigate the associations of the eGFR trajectories with the progression to ESRD and death.

Based on the results, the investigators will provide an easily accessible tool to calculate personalized probabilities of belonging to eGFR trajectories after kidney transplantation, by using datasets from prospective cohorts and post hoc analysis of randomized control trial datasets.


Clinical Trial Description

Background

Chronic kidney disease (CKD) now affects 850 million individuals worldwide, exceeding the global prevalence of diabetes, cancer and HIV/AIDS. In addition, end-stage renal disease affects 7.4 million individuals and mortality rate for individuals burdened by kidney disease is now estimated at 5 to 10 million individuals each year. Therefore, developing better diagnostic and treatment approaches for the kidney disease epidemic is a global priority, as leading professional societies and health agencies have emphasized (the US Food & Drug Administration, the National Kidney Foundation, the European Medicines Agency, the European Society of Organ Transplantation, the American Society for Transplantation and the American Society of Transplant Surgeons).

However, current approaches for investigating the relationship between eGFR course and outcomes such as ESRD and mortality have been limited by registries with an overall lack on granular data, including infrequent eGFR measurements for a single patient and convenience clinical samples. An unsupervised longitudinal approach to determine patient eGFR evolution may bring an original perspective to the traditional clinical interpretation of kidney function based on limited eGFR measurements, short-term follow-up, and standard statistical approach.

Main Outcome(s) and Measure(s)

- eGFR trajectories

- Determinants of eGFR trajectories

- Associations of eGFR trajectories with ESRD and death

- Prediction system that will provide the personalized probabilities of belonging to eGFR trajectories ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04226859
Study type Observational
Source Paris Translational Research Center for Organ Transplantation
Contact Alexandre Loupy, Professor
Email alexandre.loupy@inserm.fr
Status Recruiting
Phase
Start date January 2000
Completion date June 2020

See also
  Status Clinical Trial Phase
Withdrawn NCT04560582 - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Withdrawn NCT04216303 - Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus
Recruiting NCT03689075 - Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation Phase 4
Recruiting NCT05788276 - Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys? Phase 4
Recruiting NCT03870542 - Multicenter, Prospective Study for Urinary Exosomal Biomarkers of Kidney Allograft Tubulointerstitial Fibrosis
Active, not recruiting NCT04882254 - Normothermic Machine Perfusion: an Additional Value for Kidney Transplant Outcomes? Phase 2
Completed NCT04918199 - Human Versus Computer-based Predictions of Long Allograft Survival
Active, not recruiting NCT04897438 - Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection N/A
Enrolling by invitation NCT05285878 - Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Phase 2
Recruiting NCT06056518 - Investigating the Impact of AI on Shared Decision Making in Post-kidney Transplant Care N/A
Completed NCT05619679 - A Clinical Practice Snapshot on Pediatric Kidney Transplantation
Completed NCT06020534 - Aortoiliac Stenosis in Kidney Transplantation
Active, not recruiting NCT02960802 - Kidney Transplantation and Renal and Myocardial Perfusion N/A
Completed NCT05200949 - SURGICAL EXPERIENCE ON RENAL TRANSPLANT COMPLICATIONS
Completed NCT04258891 - Multidimensional System to Dynamically Predict Graft Survival After Kidney Transplantation
Recruiting NCT06186843 - Plant-based Diet for Kidney Transplant Recipients N/A
Active, not recruiting NCT04154267 - Protocol Biopsies in High-risk Renal Transplant Recipients N/A